GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » Quick Ratio

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Quick Ratio : 0.30 (As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Innovus Pharmaceuticals's quick ratio for the quarter that ended in Sep. 2019 was 0.30.

Innovus Pharmaceuticals has a quick ratio of 0.30. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Innovus Pharmaceuticals's Quick Ratio or its related term are showing as below:

INNV's Quick Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.32
* Ranked among companies with meaningful Quick Ratio only.

Innovus Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Innovus Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals Quick Ratio Chart

Innovus Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.07 0.43 0.39 0.36

Innovus Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.36 0.50 0.46 0.30

Competitive Comparison of Innovus Pharmaceuticals's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Innovus Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovus Pharmaceuticals's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innovus Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Innovus Pharmaceuticals's Quick Ratio falls into.



Innovus Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Innovus Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Quick Ratio (A: Dec. 2018 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(5.016-2.37)/7.353
=0.36

Innovus Pharmaceuticals's Quick Ratio for the quarter that ended in Sep. 2019 is calculated as

Quick Ratio (Q: Sep. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(4.353-1.742)/8.736
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovus Pharmaceuticals  (OTCPK:INNV) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Innovus Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
8845 Rehco Road, San Diego, CA, USA, 92121
Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.
Executives
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu director
Henry Jemil Esber director 38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz officer: EVP, CORPORATE DEVELOPMENT 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn officer: VP, CFO 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj director, officer: CHIEF EXECUTIVE OFFICER C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman officer: Chief Financial Officer ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown officer: See remarks 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew director 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness director, officer: Secretary 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack director, 10 percent owner, officer: President & CEO 175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111